Drugs / H3 mRNA / LNP Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05829356 | Apr 2023 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3 mRNA / LNP Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05829356 ↗ |
| Modality | Messenger RNA (mRNA) | “modified messenger ribonucleic acid (mRNA) vaccines encoding full length hemagglutinin (HA) sequence” NCT05829356 ↗ |
| Route | Intramuscular | “Route of Administration: Intra-Muscular” NCT05829356 ↗ |